Targets › APP
18 programs from 15 companies in 38 trials: 16 Phase 2, 13 Phase 3, 6 Phase 1, 3 Phase 4; Neurology, Other; next expected readout Nov 2026.
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. (UniProt, P05067)
Open in Phaseline: the race on APP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| JYAMS PET Research & Development | [18F]-APN-1607 Positron emission tomography (PET) imaging agent for detecting amyloid-beta pathology in A | APP | Phase 3 | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia; Alzheimer's Disease | Dec 2026 |
| Eisai | Lecanemab (BAN2401) Amyloid-beta A4 protein inhibitor | APP | Phase 3 | Early Alzheimer's Disease; Preclinical Alzheimer's Disease; Alzheimer's Disease; Alzheimer's Disease(AD) … | Dec 2026 |
| Eli Lilly | Donanemab (LY3002813) Amyloid-beta A4 protein disrupting agent | APP | Phase 3 | Alzheimer's Disease; Alzheimer Disease; Cognitive Dysfunction; Autosomal Dominant Alzheimers Disease | May 2027 |
| HTA | [18F]Fluorbetazine injection PET tracer for amyloid-beta plaque imaging | APP | Phase 3 | Mild Cognitive Impairment (MCI) | Dec 2027 |
| Roche | RO7269162 BACE1 inhibitor | APP | Phase 2 | Alzheimer's Disease | Nov 2026 |
| Columbia University | 18F-Florbetaben Amyloid PET imaging tracer that binds to amyloid-beta deposits | APP | Phase 2 | Alzheimer Disease | Dec 2026 |
| Alnylam Pharmaceuticals | ALN-APP siRNA targeting amyloid precursor protein (APP) | APP | Phase 2 | Cerebral Amyloid Angiopathy; Early-Onset Alzheimer Disease | Aug 2027 |
| Washington University School of Medicine | Gantenerumab Amyloid-beta A4 protein binding agent | APP | Phase 2 | Alzheimers Disease | Apr 2028 |
| Washington University School of Medicine | Solanezumab Amyloid-beta A4 protein binding agent | APP | Phase 2 | Alzheimers Disease | Apr 2028 |
| University of Alabama at Birmingham | [C-11]PiB PET imaging agent that binds to amyloid-beta protein | APP | Phase 2 | Alzheimer Disease | Oct 2028 |
| Alnylam Pharmaceuticals | Mivelsiran Antisense oligonucleotide targeting APP mRNA | APP | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | May 2030 |
| Akiva Mintz | 18F-Florbetapir Amyloid-beta PET imaging agent | APP | Phase 2 | Alzheimer Disease | Jun 2030 |
| Acumen Pharmaceuticals | sabirnetug anti-amyloid-beta protofibrils monoclonal antibody | APP | Phase 2 | Alzheimer Disease | – |
| Amyloid Solution | AS-S603 Small molecule targeting amyloid-beta and tau aggregates | APP, MAPT | Phase 1 | Healthy | Dec 2026 |
| Texas Tech University Health Sciences Center | Curcumin Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood- | ABCB1, APP, MAPT | Phase 1 | Bioavailability | Dec 2026 |
| Nuravax | DUVAX Vaccine targeting amyloid-beta and tau proteins | APP, MAPT | Phase 1 | Alzheimer Disease | Apr 2027 |
| Roche | RO7126209 Anti-amyloid beta monoclonal antibody | APP | Phase 1 | Alzheimers Disease | Jul 2027 |
| National Institute of Mental Health (NIMH) | 18f-florbetaben Amyloid-beta PET tracer | APP | Phase 1 | Parkinson's Disease | Apr 2029 |
Alzheimer Disease (13) Alzheimer's Disease (6) Alzheimers Disease (5) Bioavailability (1) Cognitive Dysfunction (1) Autosomal Dominant Alzheimers Disease (1) Early Alzheimer's Disease (1) Preclinical Alzheimer's Disease (1) Alzheimer's Disease(AD) (1) Alzheimer s Disease (1) Cerebral Amyloid Angiopathy (1) Early-Onset Alzheimer Disease (1)
small molecule (9), antibody (3), mixed (3), other (2), protein or peptide (1)
Alnylam Pharmaceuticals (2) Washington University School of Medicine (2) Roche (2) Texas Tech University Health Sciences Center (1) Eli Lilly (1) Eisai (1) Acumen Pharmaceuticals (1) Columbia University (1) JYAMS PET Research & Development (1) Akiva Mintz (1) Amyloid Solution (1) HTA (1) University of Alabama at Birmingham (1) Nuravax (1) National Institute of Mental Health (NIMH) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.